| Oct 17 |
Sage Therapeutics to lay off one-third staff under reorganization
|
| Oct 17 |
Sage to cut one-third of workforce, streamline drug pipeline
|
| Oct 17 |
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
|
| Oct 15 |
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
|
| Oct 10 |
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
|
| Oct 9 |
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
|
| Oct 9 |
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
|
| Oct 8 |
Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
|
| Oct 8 |
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
|
| Oct 8 |
Sage continues downslide as Alzheimer’s study fails
|
